Vesugen (KED; Lys–Glu–Asp): mechanism, evidence and research limits

Synthetic tripeptide (an oligopeptide), commonly called KED for its amino-acid sequence lysine–glutamic acid–aspartic acid. It is neither a hormone nor a mixture. Vesugen is the name used in the literature for KED in a small body of vascular, cellular and neurodegeneration-related research. It should be distinguished from a branded product name or a generic medicine name. No TGA-approved Vesugen formulation or Australian product information was identified in the official records reviewed. For this article it is therefore classified as an unapproved, research-stage peptide rather than an approved medicine; ARTG status should always be checked live before relying on it.

Vesugen is the tripeptide Lys–Glu–Asp (KED), not a hormone, topical cosmetic ingredient or multi-peptide blend. Experimental studies report changes in endothelial-cell markers, stem-cell neuronal markers and dendritic-spine measures in a 5xFAD mouse model, but these findings do not establish prevention or treatment of vascular disease, dementia or ageing in people. The human evidence located is a small Russian-language report with insufficient accessible design and safety detail. No TGA-approved Vesugen formulation was identified; research-only vials are not equivalent to an approved medicine.

Vesugen refers to KED, a three-amino-acid peptide with the sequence Lys–Glu–Asp. Published indexing identifies the substance as lysyl-glutamyl-aspartic acid, and the experimental literature calls it a short peptide or oligopeptide. That makes it a peptide, but not a glycoprotein hormone, a small molecule, a coenzyme or an inherently multi-ingredient ‘blend’. [1] [3]

The name can create a false impression of a standardised medicine. In the research literature, ‘Vesugen’ is used for KED, whereas a supplier vial is a particular commercial product whose identity, purity, sterility, excipients and intended use cannot be inferred from the peptide name alone. TGA guidance specifically warns that ‘research use only’ wording does not itself change a product’s regulatory status or make supply lawful. [7]

In a 2015 cell-culture and molecular-docking paper, Vesugen and another short peptide increased the proliferation-associated Ki-67 signal in tissue-specific cultures from young and old animals and in dissociated vascular endothelial cultures. The same paper used docking to propose contact between the peptides and a sequence in the MKI67 promoter. Docking is a computational compatibility result; it does not demonstrate that KED reaches that DNA sequence in a living person, binds it in cells, or produces a clinical vascular effect. [2]

A separate in-vitro KED study reported changes in endothelin-1, connexin expression and sirtuin-1 in normal, atherosclerotic and restenotic endothelium. These are measured molecular markers in cultured tissue, not validated evidence that KED repairs arteries or reduces cardiovascular events. The studies do not establish a receptor, human pharmacokinetics, tissue exposure, dose–response relationship or a causal pathway from any marker to patient benefit. [3]

The 2016 study titled ‘Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis’ was an in-vitro comparison of endothelium described as normal, atherosclerotic and restenotic. Its abstract reports that KED normalised elevated endothelin-1 expression during atherosclerosis and restenosis, restored connexin-associated cell interactions, and increased sirtuin-1 expression. Those are observations within the authors’ laboratory model. [3]

A similarly named 2014 paper is sometimes cited as KED evidence, but its PubMed record identifies the tested peptide as Lys–Glu–Trp (KEW), not Lys–Glu–Asp (KED). It used cultured aortic endothelial cells from patients with atherosclerosis and reported recovery of Cx37, Cx40 and VEGF expression at the tested concentrations. It is therefore not direct Vesugen evidence and should not be silently substituted into a KED evidence summary. [10]

A 2021 primary study used 5xFAD mice crossed with an M line (5xFAD-M), a transgenic amyloid-pathology model carrying human APP and PSEN1 mutations. KED was administered daily by intraperitoneal injection from 2 to 4 months of age at 400 micrograms/kg; this is a mouse-study method, not a human regimen. In the combined-sex analysis, KED did not significantly alter total CA1 dendritic-spine density but increased the proportion of mushroom spines and reduced thin spines relative to saline-treated 5xFAD-M mice. [1]

The electrophysiology result was more tentative: the authors reported a positive trend toward restoration of hippocampal long-term potentiation, without statistical significance. Sex-specific results also differed, with stronger spine-density findings reported in males than females. The study measured cellular and electrophysiological proxies, not demonstrated prevention of dementia or human cognitive benefit. A 2025 correction replaced duplicated/confused male and female confocal figures; the authors stated that the scientific conclusions were unaffected, but the correction is still important context when reading the imaging claims. [1] [5]

In a 2019 laboratory study, researchers isolated human periodontal-ligament stem cells from 10 healthy donors aged 20–40 years. KED at 0.01 micrograms/mL, refreshed every three days, was tested in culture for 10 days alongside other peptides and their mixture. KED was associated with increased GAP43 and Nestin expression, markers the authors used to examine early neuronal differentiation. This is a controlled human-cell experiment, not treatment of people and not evidence for neuroregeneration in a patient. [4]

The experiment also makes an important comparison point: a mixture of KED with AED, KE and AEDG was separately tested in vitro. That does not validate a combined human protocol, establish a safe interaction profile, or show that a supplier’s blend behaves like the individual components. Results from a defined cell-culture mixture should not be generalised to injectable or oral ‘stacks’. [4] [7]

The human publication located was a 2015 Russian-language report on Vesugen and Pinealon in people with chronic polymorbidity and organic brain syndrome in remission. Its English abstract says 32 participants aged 41–83 years took part, but the reported sex totals (18 men and 12 women) add to 30. It describes changes in ‘biological age’ indicators and laboratory measures, and calls Vesugen’s effect more visible than Pinealon’s. [6]

The accessible record does not provide enough information to establish randomisation, blinding, a concurrent control group, prespecified outcomes, attrition, product quality, treatment allocation, dosing details or a systematic adverse-event analysis. It also studied two peptides in a clinically complex population. For those reasons, it cannot establish that KED is effective or safe for ageing, cognition, vascular disease or any other indication. [6]

There is no adequate product-specific human safety database for Vesugen in the sources reviewed. Unknowns include absorption and distribution by route, metabolism, interactions, contraindications, immunogenicity, effects of chronic exposure, and whether a commercial vial contains the stated peptide at the stated strength. An experimental finding in a cell dish or mouse does not resolve any of these questions. [1] [3] [4] [6]

The TGA warns that unapproved peptide products have not been assessed for quality, safety or effectiveness and may present risks from inaccurate labelling, contamination, non-sterility, infection and local tissue damage. The regulator lists serious reactions reported across unapproved peptide products, including severe allergy and systemic inflammatory illness. These reports are not Vesugen-specific incidence data, so they should not be represented as a known KED adverse-effect rate; they explain why unverified products merit particular caution. [7] [9]

In Australia, peptide products are therapeutic goods. The ARTG is the TGA’s public reference database for therapeutic goods that can be supplied in Australia, and, unless an exemption applies, goods not in the ARTG cannot be supplied. No approved Vesugen formulation or Australian product information was identified in the official records reviewed for this article, so it should not be described as TGA-approved. The live ARTG, searched by both ‘Vesugen’ and active-ingredient terms, is the appropriate source for a current check. [7] [8]

An unapproved product is not automatically a consumer-access medicine. The TGA says particular clinical access pathways may exist through appropriately registered practitioners, including the Special Access Scheme for individual patients and the Authorised Prescriber scheme for multiple patients, but unapproved goods have not been evaluated by the TGA for quality, safety or efficacy and practitioners must consider approved options first. That framework is not a recommendation for KED or evidence of a clinical indication. [9]

The most defensible reading of the evidence is tiered: first, confirm that the study actually used KED rather than a similarly named peptide such as KEW; second, identify whether the result was in cells, mice or people; third, distinguish a marker change from a clinical outcome; and finally, check whether methods and safety reporting allow the result to be replicated. On that scale, Vesugen remains a research-stage tripeptide with unresolved clinical value. [1] [3] [4] [6] [10]

Is Vesugen an approved medicine in Australia?

No TGA-approved Vesugen formulation or Australian product information was identified in the official records reviewed. The TGA states that, unless exempt, therapeutic goods not included in the ARTG cannot be supplied in Australia. Confirm any current claim through the live ARTG rather than a supplier page. [7] [8]

Is Vesugen really a peptide?

Yes. Vesugen is the KED tripeptide, Lys–Glu–Asp (lysyl-glutamyl-aspartic acid). It is not a glycoprotein hormone, small molecule, coenzyme or inherently a blend. [1] [3]

Does the 5xFAD study show that Vesugen treats Alzheimer’s disease?

No. It reports changes in CA1 dendritic-spine measures in a particular transgenic mouse model and a non-significant trend in long-term potentiation. It did not demonstrate a human clinical outcome or establish disease treatment. The study’s imaging figures were later corrected. [1] [5]

Can a research-only vial be treated as a medicine if it says it contains KED?

No. The TGA warns that a ‘research use only’ disclaimer does not change regulatory status or make supply lawful. It also does not verify identity, quality, sterility or safety of a vial. [7]

Is there a validated Vesugen dose, route, storage rule or combination protocol for people?

Not from the evidence reviewed. The KED administration details located were study-specific animal or cell-culture methods, while the limited human report lacks sufficient accessible protocol and safety detail. There is no basis here for a universal human schedule, reconstitution instruction, storage rule or blend protocol. [1] [4] [6]

The Vesugen evidence base is small, largely produced by overlapping research networks, and methodologically heterogeneous. Several reports are available only as English abstracts of Russian-language articles, restricting verification of protocol, randomisation, controls, attrition, statistical plan and safety capture. The direct vascular evidence is in vitro; the strongest disease-model work is in a genetically engineered mouse model with sex-dependent findings and a later figure correction; and the only located human report is small and inadequately described, with an internal participant-count discrepancy. Neither a confirmed pharmacological target nor reliable human pharmacokinetics, product quality standards, dosing, route, storage requirements, interaction profile, long-term safety profile or clinical efficacy has been established. Supplier claims and research-only vials should not be used to fill those evidence gaps.

1. [1] Neuroprotective Effects of Tripeptides—Epigenetic Regulators in Mouse Model of Alzheimer’s Disease. Controlled preclinical study in 5xFAD and 5xFAD-M transgenic mouse models; daily intraperitoneal KED or EDR from 2 to 4 months, with hippocampal long-term potentiation and CA1 dendritic-spine analyses.
2. [2] Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation in aging. Cell-culture experiments using tissue-specific cultures from young and old animals and dissociated vascular endothelial cultures, plus molecular docking to the MKI67 promoter region.
3. [3] Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis. In-vitro analysis of KED effects on signal-molecule expression in normal, atherosclerotic and restenotic endothelium.
4. [4] Effect of short peptides on neuronal differentiation of stem cells. In-vitro study of primary human periodontal-ligament stem cells from 10 healthy donors, exposed to KED, three other peptides or their defined mixture; GAP43 and Nestin were measured.
5. [5] Correction: Khavinson et al. Neuroprotective Effects of Tripeptides—Epigenetic Regulators in Mouse Model of Alzheimer’s Disease. Pharmaceuticals 2021, 14, 515. Post-publication correction of the 2021 mouse article’s Figures 5 and 8, which had been the same images described differently.
6. [6] Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission. Small human study reporting Vesugen and Pinealon use in adults with chronic polymorbidity and organic brain syndrome in remission; accessible record has limited methodological detail.
7. [7] Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. TGA regulatory and safety guidance for unapproved peptide products.
8. [8] Searching the Australian Register of Therapeutic Goods (ARTG). Official description of the ARTG, its searchable fields and supply context.
9. [9] Access an unapproved therapeutic good (health practitioners). Official TGA guidance on practitioner-only pathways for unapproved therapeutic goods.
10. [10] Effects of Lys-Glu-Trp peptide on cell-cell interactions and vascular endothelium proliferation under normal conditions and during atherosclerosis. Cultured aortic endothelial cells from patients with atherosclerosis treated with Lys–Glu–Trp (KEW), at 4 or 40 micrograms/mL.